Exact Mass: 327.20205940000005

Exact Mass Matches: 327.20205940000005

Found 383 metabolites which its exact mass value is equals to given mass value 327.20205940000005, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Butorphanol

(1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene-4,10-diol

C21H29NO2 (327.2198174)


Butorphanol is only found in individuals that have used or taken this drug. It is a synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain. [PubChem]The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Butorphanol is a mixed agonist-antagonist that exerts antagonistic or partially antagonistic effects at mu opiate receptor sites, but is thought to exert its agonistic effects principally at the kappa and sigma opiate receptors. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AF - Morphinan derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists D019141 - Respiratory System Agents > D000996 - Antitussive Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics

   
   

MLS002608513

17-Methylandrosta-2,4-dieno[2,3-d]isoxazol-17beta-ol

C21H29NO2 (327.2198174)


   

Azaperone

Azaperone

C19H22FN3O (327.1746814)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Azaperone (R-1929) acts as a dopamine antagonist but also has some antihistaminic and anticholinergic properties. Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic agent with antiemetic effects, which is used mainly as a tranquilizer in veterinary medicine.

   

Melitracen hydrochloride

Melitracen hydrochloride

C21H26ClN (327.1753666000001)


D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent Melitracen hydrochloride is an orally active biphasic antidepressant and antianxiety agent. Melitracen hydrochloride can inhibit the uptake of Norepinephrine and 5-HT (serotonin) through the presynaptic membrane inducing the increase of monoamine transmitters in synaptic space[1][2].

   

(9E)-9-nitrooctadecenoic Acid

(9E)-9-nitrooctadec-9-enoic acid

C18H33NO4 (327.2409458)


(9E)-9-nitrooctadecenoic Acid, also known as (e)-9-Nitrooctadec-9-enoate, is classified as a member of the Long-chain fatty acids. Long-chain fatty acids are fatty acids with an aliphatic tail that contains between 13 and 21 carbon atoms. (9E)-9-nitrooctadecenoic Acid is considered to be practically insoluble (in water) and acidic. (9E)-9-nitrooctadecenoic Acid is a fatty acid lipid molecule

   

(9E)-10-nitrooctadecenoic Acid

(9E)-10-nitrooctadec-9-enoic acid

C18H33NO4 (327.2409458)


(9E)-10-nitrooctadecenoic Acid, also known as 10-Nitroelaidic acid or (e)-10-Nitrooctadec-9-enoate, is classified as a member of the Long-chain fatty acids. Long-chain fatty acids are fatty acids with an aliphatic tail that contains between 13 and 21 carbon atoms. (9E)-10-nitrooctadecenoic Acid is considered to be practically insoluble (in water) and acidic. (9E)-10-nitrooctadecenoic Acid is a fatty acid lipid molecule

   

Simulansine

2-(3-hydroxy-4-methylpentyl)-2,6-dimethyl-2H,5H,6H-pyrano[3,2-c]quinolin-5-one

C20H25NO3 (327.18343400000003)


Alkaloid from root bark of Zanthoxylum simulans (Szechuan pepper). Simulansine is found in herbs and spices and fruits. Simulansine is found in fruits. Simulansine is an alkaloid from root bark of Zanthoxylum simulans (Szechuan pepper).

   

Retrofractamide A

(2E,4E,8E)-9-(2H-1,3-Benzodioxol-5-yl)-N-(2-methylpropyl)nona-2,4,8-trienimidate

C20H25NO3 (327.18343400000003)


Retrofractamide A is found in herbs and spices. Retrofractamide A is an alkaloid from the above-ground parts of Piper retrofractum (Javanese long pepper) and the fruits of Piper nigrum (pepper). Alkaloid from the above-ground parts of Piper retrofractum (Javanese long pepper) and the fruits of Piper nigrum (pepper). Retrofractamide A is found in herbs and spices and pepper (spice).

   

(+)-O-Methylarmepavine

6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-1,2,3,4-tetrahydroisoquinoline

C20H25NO3 (327.18343400000003)


(+)-O-Methylarmepavine is found in fruits. (+)-O-Methylarmepavine is an alkaloid from Annona squamosa (sugar apple

   

(2E,8E)-Piperamide-C9:2

(2E,8Z)-9-(2H-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)nona-2,8-dien-1-one

C20H25NO3 (327.18343400000003)


(2E,8E)-Piperamide-C9:2 is found in herbs and spices. (2E,8E)-Piperamide-C9:2 is a constituent of pepper fruits (Piper nigrum). Constituent of pepper fruits (Piper nigrum). (2E,8E)-Piperamide-C9:2 is found in herbs and spices.

   

Norelgestromin

15-Ethyl-14-ethynyl-5-(hydroxyimino)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-ol

C21H29NO2 (327.2198174)


Norelgestromin is only found in individuals that have used or taken this drug. It is a drug used in contraception. Norelgestromin is the active progestin responsible for the progestational activity that occurs in women after application of ORTHO EVRA patch. Norelgestromin inhibits estrone sulfatase, which converts sulfated steroid precursors to estrogen during pregnancy. Norgelgestromin/ethinylestradiol suppresses follicular development, induces changes to the endometrium, which decreases chances of implantation and thickens the cervical mucus, impeding sperm swimming into the uterus. It also has similar agonisting binding affinities as its parent compound, Norgestimate, for progesterone and estrogen receptors. D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents

   

N1-(2-Methoxy-4-methylbenzyl)-n2-(2-(pyridin-2-yl) ethyl)oxalamide

N-[(2-methoxy-4-methylphenyl)methyl]-N-[2-(pyridin-2-yl)ethyl]ethanediamide

C18H21N3O3 (327.1582836)


N1-(2-Methoxy-4-methylbenzyl)-n2-(2-(pyridin-2-yl) ethyl)oxalamide is used as a food additive [EAFUS] ("EAFUS: Everything Added to Food in the United States. [http://www.eafus.com/]")

   

Cinereain

(4E)-4-(2-methylpropylidene)-7-(propan-2-yl)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,11,13-tetraene-6,9-dione

C18H21N3O3 (327.1582836)


Cinereain is found in cereals and cereal products. Cinereain is isolated from Botrytis cinerea on sunflower seed. Isolated from Botrytis cinerea on sunflower seed. Cinereain is found in cereals and cereal products.

   

3,4-dimethylideneheptanedioylcarnitine

3-[(6-carboxy-3,4-dimethylidenehexanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H25NO6 (327.168179)


3,4-dimethylideneheptanedioylcarnitine is an acylcarnitine. More specifically, it is an 3,4-dimethylideneheptanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4-dimethylideneheptanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,4-dimethylideneheptanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E,6Z)-3-Hydroxydeca-4,6-dienoylcarnitine

3-[(3-hydroxydeca-4,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO5 (327.2045624)


(4E,6Z)-3-Hydroxydeca-4,6-dienoylcarnitine is an acylcarnitine. More specifically, it is an (4E,6Z)-3-hydroxydeca-4,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6Z)-3-Hydroxydeca-4,6-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E,6Z)-3-Hydroxydeca-4,6-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6Z,8E)-3-Hydroxydeca-6,8-dienoylcarnitine

3-[(3-hydroxydeca-6,8-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO5 (327.2045624)


(6Z,8E)-3-Hydroxydeca-6,8-dienoylcarnitine is an acylcarnitine. More specifically, it is an (6Z,8E)-3-hydroxydeca-6,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z,8E)-3-Hydroxydeca-6,8-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6Z,8E)-3-Hydroxydeca-6,8-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E,7E)-3-Hydroxydeca-4,7-dienoylcarnitine

3-[(3-hydroxydeca-4,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO5 (327.2045624)


(4E,7E)-3-Hydroxydeca-4,7-dienoylcarnitine is an acylcarnitine. More specifically, it is an (4E,7E)-3-hydroxydeca-4,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,7E)-3-Hydroxydeca-4,7-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E,7E)-3-Hydroxydeca-4,7-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5Z,7E)-3-Hydroxydeca-5,7-dienoylcarnitine

3-[(3-hydroxydeca-5,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H29NO5 (327.2045624)


(5Z,7E)-3-Hydroxydeca-5,7-dienoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,7E)-3-hydroxydeca-5,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,7E)-3-Hydroxydeca-5,7-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5Z,7E)-3-Hydroxydeca-5,7-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6E)-Undec-6-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-6-enoyloxy)butanoate

C18H33NO4 (327.2409458)


(6E)-Undec-6-enoylcarnitine is an acylcarnitine. More specifically, it is an (6E)-undec-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E)-Undec-6-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6E)-Undec-6-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E)-Undec-2-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-2-enoyloxy)butanoate

C18H33NO4 (327.2409458)


(2E)-Undec-2-enoylcarnitine is an acylcarnitine. More specifically, it is an (2E)-undec-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E)-Undec-2-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E)-Undec-2-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5E)-Undec-5-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-5-enoyloxy)butanoate

C18H33NO4 (327.2409458)


(5E)-Undec-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5E)-undec-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E)-Undec-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5E)-Undec-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E)-Undec-4-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-4-enoyloxy)butanoate

C18H33NO4 (327.2409458)


(4E)-Undec-4-enoylcarnitine is an acylcarnitine. More specifically, it is an (4E)-undec-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E)-Undec-4-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E)-Undec-4-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(7E)-Undec-7-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-7-enoyloxy)butanoate

C18H33NO4 (327.2409458)


(7E)-Undec-7-enoylcarnitine is an acylcarnitine. More specifically, it is an (7E)-undec-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7E)-Undec-7-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (7E)-Undec-7-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Undec-3-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-3-enoyloxy)butanoate

C18H33NO4 (327.2409458)


Undec-3-enoylcarnitine is an acylcarnitine. More specifically, it is an undec-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undec-3-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undec-3-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Undec-9-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-9-enoyloxy)butanoate

C18H33NO4 (327.2409458)


Undec-9-enoylcarnitine is an acylcarnitine. More specifically, it is an undec-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undec-9-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undec-9-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Undec-8-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-8-enoyloxy)butanoate

C18H33NO4 (327.2409458)


Undec-8-enoylcarnitine is an acylcarnitine. More specifically, it is an undec-8-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undec-8-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undec-8-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

undec-10-enoylcarnitine

4-(trimethylazaniumyl)-3-(undec-10-enoyloxy)butanoate

C18H33NO4 (327.2409458)


undec-10-enoylcarnitine is an acylcarnitine. More specifically, it is an undec-10-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. undec-10-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine undec-10-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Nona-4,7-dienedioylcarnitine

3-[(8-carboxyocta-4,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H25NO6 (327.168179)


nona-4,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an nona-4,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. nona-4,7-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nona-4,7-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Nona-3,7-dienedioylcarnitine

3-[(8-carboxyocta-3,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H25NO6 (327.168179)


nona-3,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an nona-3,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. nona-3,7-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nona-3,7-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Nona-4,6-dienedioylcarnitine

3-[(8-Carboxyocta-4,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H25NO6 (327.168179)


nona-4,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an nona-4,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. nona-4,6-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nona-4,6-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,7E)-Nona-2,7-dienedioylcarnitine

3-[(8-carboxyocta-2,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H25NO6 (327.168179)


(2E,7E)-nona-2,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (2E,7E)-nona-2,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,7E)-nona-2,7-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,7E)-nona-2,7-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Nona-3,6-dienedioylcarnitine

3-[(8-carboxyocta-3,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H25NO6 (327.168179)


Nona-3,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an nona-3,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. nona-3,6-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nona-3,6-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Nona-5,7-dienedioylcarnitine

3-[(8-carboxyocta-5,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H25NO6 (327.168179)


Nona-5,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an nona-5,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. nona-5,7-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nona-5,7-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(S)-Tert-Butyl (3-hydroxy-1,1-diphenylpropan-2-yl)carbamate

(S)-Tert-butyl (3-hydroxy-1,1-diphenylpropan-2-yl)carbamic acid

C20H25NO3 (327.18343400000003)


   

1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-7-(3-(methylphenylamino)propyl)-

1,3-dimethyl-7-{3-[methyl(phenyl)amino]propyl}-2,3,6,7-tetrahydro-1H-purine-2,6-dione

C17H21N5O2 (327.1695166)


   

1-Butyl-3-(1-naphthoyl)indole

(1-Butyl-1H-indole-3-yl)-1-naphthalenyl methanone

C23H21NO (327.1623056)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D063385 - Cannabinoid Receptor Modulators D018377 - Neurotransmitter Agents > D063385 - Cannabinoid Receptor Modulators > D063386 - Cannabinoid Receptor Agonists

   

10-Nitrooleate

10-Nitro-9(e)-octadec-9-enoic acid

C18H33NO4 (327.2409458)


   

Azaperone

1-(4-fluorophenyl)-4-[4-(pyridin-2-yl)piperazin-1-yl]butan-1-one

C19H22FN3O (327.1746814)


   

BENACTYZINE

2-(Diethylamino)ethyl 2-hydroxy-2,2-diphenylacetic acid

C20H25NO3 (327.18343400000003)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists

   

Flestolol

3-{[1-(carbamoylamino)-2-methylpropan-2-yl]amino}-2-hydroxypropyl 2-fluorobenzoate

C15H22FN3O4 (327.15942640000003)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists

   

Ketotrilostane

5-hydroxy-2,16-dimethyl-15-oxo-7-oxapentacyclo[9.7.0.0^{2,8}.0^{6,8}.0^{12,16}]octadec-4-ene-4-carbonitrile

C20H25NO3 (327.18343400000003)


   

Nitro-oleic acid

2-nitrooctadec-9-enoic acid

C18H33NO4 (327.2409458)


   

18-Nitrooctadec-9-enoic acid

18-Nitrooctadec-9-enoic acid

C18H33NO4 (327.2409458)


   

Traxoprodil

1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol

C20H25NO3 (327.18343400000003)


   

(8R,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-3-nitroso-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol

(8R,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-3-nitroso-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol

C21H29NO2 (327.2198174)


   

2-trans-8-trans-Piperamide-C-9-2

(2E,8E)-9-(2H-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)nona-2,8-dien-1-one

C20H25NO3 (327.18343400000003)


2-trans-8-trans-piperamide-c-9-2 is a member of the class of compounds known as benzodioxoles. Benzodioxoles are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered unsaturated ring of two oxygen atoms and three carbon atoms. 2-trans-8-trans-piperamide-c-9-2 is practically insoluble (in water) and a moderately basic compound (based on its pKa). 2-trans-8-trans-piperamide-c-9-2 can be found in pepper (spice), which makes 2-trans-8-trans-piperamide-c-9-2 a potential biomarker for the consumption of this food product.

   
   
   

Cropodine

1beta,2-Dihydromonocrotaline

C16H25NO6 (327.168179)


   
   
   
   
   
   

10,11-Dihydro-8-(1-methylethyl)-11-(2-methylpropylidene)-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione

10,11-Dihydro-8-(1-methylethyl)-11-(2-methylpropylidene)-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione

C18H21N3O3 (327.1582836)


   

(+)-O-Methylarmepavine

6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-1,2,3,4-tetrahydroisoquinoline

C20H25NO3 (327.18343400000003)


   

JWH-015

(2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone

C23H21NO (327.1623056)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D063385 - Cannabinoid Receptor Modulators D018377 - Neurotransmitter Agents > D063385 - Cannabinoid Receptor Modulators > D063386 - Cannabinoid Receptor Agonists

   
   

JWH-073

(1-butyl-1H-indol-3-yl)-1-naphthalenyl-methanone

C23H21NO (327.1623056)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D063385 - Cannabinoid Receptor Modulators D018377 - Neurotransmitter Agents > D063385 - Cannabinoid Receptor Modulators > D063386 - Cannabinoid Receptor Agonists CONFIDENCE standard compound; INTERNAL_ID 1704

   
   

BENACTYZINE

BENACTYZINE

C20H25NO3 (327.18343400000003)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists

   

AMINOPROMAZINE

AMINOPROMAZINE

C19H25N3S (327.176909)


C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   

N-(3-Hydroxytetradecanoyl)-DL-homoserine lactone

N-(3-Hydroxytetradecanoyl)-DL-homoserine lactone

C18H33NO4 (327.2409458)


   
   
   
   
   
   

18-aminoavarone|3-aminoavarone

18-aminoavarone|3-aminoavarone

C21H29NO2 (327.2198174)


   

(-)-4-<2-(dimethylamino)ethyl>phenyl beta-D-glucopyranoside|(-)-4-[2-(dimethylamino)ethyl]phenyl beta-D-glucopyranoside|hordenine-4-O-beta-D-glucoside

(-)-4-<2-(dimethylamino)ethyl>phenyl beta-D-glucopyranoside|(-)-4-[2-(dimethylamino)ethyl]phenyl beta-D-glucopyranoside|hordenine-4-O-beta-D-glucoside

C16H25NO6 (327.168179)


   

Fortuneine

4,5,17-trimethoxy-11-azatetracyclo[9.7.0.01,14.02,7]octadeca-2,4,6,13,15-pentaene

C20H25NO3 (327.18343400000003)


   
   
   

3-acetylviridiflorine

3-acetylviridiflorine

C17H29NO5 (327.2045624)


   
   
   

19-aminoavarone|4-aminoavarone

19-aminoavarone|4-aminoavarone

C21H29NO2 (327.2198174)


   

N-(14-methylallyl)norgalanthamine|N-14-methylallylnorgalanthamin

N-(14-methylallyl)norgalanthamine|N-14-methylallylnorgalanthamin

C20H25NO3 (327.18343400000003)


   
   

17alpha-cyanomethylestra-1,3,5(10)-triene-3,16xi,17-triol

17alpha-cyanomethylestra-1,3,5(10)-triene-3,16xi,17-triol

C20H25NO3 (327.18343400000003)


   

3,20-dioxo-11alpha-hydroxycona-1,4-diene|norkurchamide

3,20-dioxo-11alpha-hydroxycona-1,4-diene|norkurchamide

C20H25NO3 (327.18343400000003)


   
   

17alpha-cyanomethyl-11beta,17-dihydroxy-4,9-estradien-3-one|17alpha-Cyanomethyl-11beta,17beta-dihydroxy-estra-4,9-dien-3-on

17alpha-cyanomethyl-11beta,17-dihydroxy-4,9-estradien-3-one|17alpha-Cyanomethyl-11beta,17beta-dihydroxy-estra-4,9-dien-3-on

C20H25NO3 (327.18343400000003)


   
   
   

JWH 073 2-naphthyl-N-(1,1-dimethylethyl) isomer

JWH 073 2-naphthyl-N-(1,1-dimethylethyl) isomer

C23H21NO (327.1623056)


   
   

UR-144 N(4-hydroxypentyl)

UR-144 N(4-hydroxypentyl)

C21H29NO2 (327.2198174)


   

(1-(sec-butyl)-1H-indol-3-yl)(naphthalen-2-yl)-methanone

(1-(sec-butyl)-1H-indol-3-yl)(naphthalen-2-yl)-methanone

C23H21NO (327.1623056)


   
   
   
   

Retrofractamide A

(2E,4E,8E)-9-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)nona-2,4,8-trienamide

C20H25NO3 (327.18343400000003)


   

Sinapine hydroxide

Sinapine (hydroxide)

C16H25NO6 (327.168179)


   

Tetrameprozine

AMINOPROMAZINE

C19H25N3S (327.176909)


[Raw Data] CB198_Tetrameprozine_pos_50eV_CB000070.txt [Raw Data] CB198_Tetrameprozine_pos_40eV_CB000070.txt [Raw Data] CB198_Tetrameprozine_pos_30eV_CB000070.txt [Raw Data] CB198_Tetrameprozine_pos_20eV_CB000070.txt [Raw Data] CB198_Tetrameprozine_pos_10eV_CB000070.txt

   

C18H21N3O3_6H-Oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione, 10,11-dihydro-8-(1-methylethyl)-11-(2-methylpropylidene)-, (11Z)

NCGC00384906-01_C18H21N3O3_6H-Oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione, 10,11-dihydro-8-(1-methylethyl)-11-(2-methylpropylidene)-, (11Z)-

C18H21N3O3 (327.1582836)


   

C18H21N3O3_2H-Pyrazino[2,1-b]quinazoline-3,6(1H,4H)-dione, 10-hydroxy-4-(1-methylethyl)-1-(2-methylpropylidene)-, (1Z,4S)

NCGC00380832-01_C18H21N3O3_2H-Pyrazino[2,1-b]quinazoline-3,6(1H,4H)-dione, 10-hydroxy-4-(1-methylethyl)-1-(2-methylpropylidene)-, (1Z,4S)-

C18H21N3O3 (327.1582836)


   

3-hydroxy-C14 homoserine lactone

3-hydroxy-N-(2-oxooxolan-3-yl)tetradecanamide

C18H33NO4 (327.2409458)


CONFIDENCE standard compound; INTERNAL_ID 218

   
   
   

Levonorgestrel oxime

Levonorgestrel oxime

C21H29NO2 (327.2198174)


   

PC(O-5:0/0:0)[R]

3,5,8-Trioxa-4-phosphatridecan-1-aminium, 4-hydroxy-7-(hydroxymethyl)-N,N,N-trimethyl-, inner salt, 4-oxide, (R)-

C13H30NO6P (327.18106500000005)


   
   
   

9-nitrooctadec-9E-enoic acid

9-nitrooctadec-9E-enoic acid

C18H33NO4 (327.2409458)


   

10-nitro-9E-octadecenoic acid

10-nitro-9E-octadecenoic acid

C18H33NO4 (327.2409458)


   
   

(±)-UR-144 N-(4-hydroxypentyl) metabolite

(±)-UR-144 N-(4-hydroxypentyl) metabolite

C21H29NO2 (327.2198174)


   

N1-(2-Methoxy-4-methylbenzyl)-N2-(2-(pyridin-2-YL)ethyl)oxalamide

N-[(2-methoxy-4-methylphenyl)methyl]-N-[2-(pyridin-2-yl)ethyl]ethanediamide

C18H21N3O3 (327.1582836)


   

Cinereain

(4E)-4-(2-methylpropylidene)-7-(propan-2-yl)-15-oxa-2,5,8-triazatricyclo[8.5.0.0^{3,8}]pentadeca-1(10),2,11,13-tetraene-6,9-dione

C18H21N3O3 (327.1582836)


   

Brachyamide b

(2E,8Z)-9-(2H-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)nona-2,8-dien-1-one

C20H25NO3 (327.18343400000003)


   

Simulansine

2-(3-hydroxy-4-methylpentyl)-2,6-dimethyl-2H,5H,6H-pyrano[3,2-c]quinolin-5-one

C20H25NO3 (327.18343400000003)


   

JWH 018 2-naphthyl isomer

JWH 018 2-naphthyl isomer

C23H21NO (327.1623056)


   

JWH 073 N-(2-methylpropyl) isomer

JWH 073 N-(2-methylpropyl) isomer

C23H21NO (327.1623056)


   

JWH 073 N-(1-methylpropyl) isomer

JWH 073 N-(1-methylpropyl) isomer

C23H21NO (327.1623056)


   

JWH 073 N-(1,1-dimethylethyl) isomer

JWH 073 N-(1,1-dimethylethyl) isomer

C23H21NO (327.1623056)


   

JWH 073 2-naphthyl isomer

JWH 073 2-naphthyl isomer

C23H21NO (327.1623056)


   

JWH 073 2-naphthyl-N-(2-methylpropyl) isomer

JWH 073 2-naphthyl-N-(2-methylpropyl) isomer

C23H21NO (327.1623056)


   

JWH 073 2-naphthyl-N-(1-methylpropyl) isomer

JWH 073 2-naphthyl-N-(1-methylpropyl) isomer

C23H21NO (327.1623056)


   

9-nitro-9E-octadecenoic acid

9-nitro-9E-octadecenoic acid

C18H33NO4 (327.2409458)


   

NA 18:2;O3

N-(3-Hydroxy-9Z-hexadecenoyl) glycine

C18H33NO4 (327.2409458)


   

LPC O-5:0

1-pentyl-sn-glycero-3-phosphocholine

C13H30NO6P (327.18106500000005)


   
   

3-[3-(3-aminopropyl)-2,4,8,10-tetraoxaspiro[5.5]undecan-9-yl]propan-1-amine,prop-2-enenitrile

3-[3-(3-aminopropyl)-2,4,8,10-tetraoxaspiro[5.5]undecan-9-yl]propan-1-amine,prop-2-enenitrile

C16H29N3O4 (327.21579540000005)


   

(2S,3S)-3-(ACETYLOXY)-5-[2-(DIMETHYLAMINO)ETHYL]-2,3-DIHYDRO-2-(4-HYDROXYPHENYL)-1,5-BENZOTHIAZEPIN-4(5H)-ONE

(2S,3S)-3-(ACETYLOXY)-5-[2-(DIMETHYLAMINO)ETHYL]-2,3-DIHYDRO-2-(4-HYDROXYPHENYL)-1,5-BENZOTHIAZEPIN-4(5H)-ONE

C21H29NO2 (327.2198174)


   

(5-Isopropyl-3-methyl-1,2-oxazol-4-yl)[4-(3-methylphenyl)-1-piper azinyl]methanone

(5-Isopropyl-3-methyl-1,2-oxazol-4-yl)[4-(3-methylphenyl)-1-piper azinyl]methanone

C19H25N3O2 (327.194667)


   

1-HEXYL-4-(4-ISOTHIOCYANATOPHENYL)-BICYC LO(2.2.2)OCTANE

1-HEXYL-4-(4-ISOTHIOCYANATOPHENYL)-BICYC LO(2.2.2)OCTANE

C21H29NS (327.20205940000005)


   
   

1-{3-[4-(3-TRIFLUOROMETHYL-PHENYL)-PIPERAZIN-1-YL]-AZETIDIN-1-YL}-ETHANONE

1-{3-[4-(3-TRIFLUOROMETHYL-PHENYL)-PIPERAZIN-1-YL]-AZETIDIN-1-YL}-ETHANONE

C16H20F3N3O (327.15583860000004)


   
   

Ammonium dodecyl poly oxyethylene sulfate

Ammonium dodecyl poly oxyethylene sulfate

C14H33NO5S (327.20793280000004)


   

Levobunolol hydrochloride

Levobunolol hydrochloride

C17H26ClNO3 (327.16011160000005)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent Levobunolol (l-Bunolol) hydrochloride is a potent and nonselective β-adrenergic receptor antagonist. Levobunolol hydrochloride is an ocular hypotensive agent and lowers mean intraocular pressure (IOP). Levobunolol hydrochloride can be used for glaucoma and superior oblique myokymia (SOM) research[1][2][3].

   

1H-INDAZOLE, 6-FLUORO-1-(2-FLUOROPHENYL)-3-(1-METHYL-4-PIPERIDINYL)-

1H-INDAZOLE, 6-FLUORO-1-(2-FLUOROPHENYL)-3-(1-METHYL-4-PIPERIDINYL)-

C19H19F2N3 (327.1546958)


   
   

N-[(1R)-2-[1,1-Biphenyl]-4-yl-1-(hydroxymethyl)ethyl]carbamic acid 1,1-dimethylethyl ester

N-[(1R)-2-[1,1-Biphenyl]-4-yl-1-(hydroxymethyl)ethyl]carbamic acid 1,1-dimethylethyl ester

C20H25NO3 (327.18343400000003)


   

4-(Furfurylaminocarbonyl)benzeneboronic acid pinacol ester

4-(Furfurylaminocarbonyl)benzeneboronic acid pinacol ester

C18H22BNO4 (327.16418020000003)


   

N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine methyl ester

N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine methyl ester

C15H25N3O3S (327.161654)


   

N-(tert-Butoxycarbonyl)-b-phenyl-L-phenylalaninol

N-(tert-Butoxycarbonyl)-b-phenyl-L-phenylalaninol

C20H25NO3 (327.18343400000003)


   

Difemerine

Difemerine

C20H25NO3 (327.18343400000003)


A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AA - Synthetic anticholinergics, esters with tertiary amino group C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent

   
   

Methanone, [4-(2,3-dimethylphenyl)-1-piperazinyl](3-ethyl-5-methyl-4-isoxazolyl)

Methanone, [4-(2,3-dimethylphenyl)-1-piperazinyl](3-ethyl-5-methyl-4-isoxazolyl)

C19H25N3O2 (327.194667)


   

1,3,5-tris(azidomethyl)-2,4,6-triethylbenzene

1,3,5-tris(azidomethyl)-2,4,6-triethylbenzene

C15H21N9 (327.1919826)


   

4-Aminobenzo-18-crown-6

4-Aminobenzo-18-crown-6

C16H25NO6 (327.168179)


   

n-ethyl-carbazol-3-aldehyde-n-methyl-n-phenyl-hydrazone

n-ethyl-carbazol-3-aldehyde-n-methyl-n-phenyl-hydrazone

C22H21N3 (327.17353860000003)


   

2-Cyano-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxa-borolan-2-yl)-phenyl]-acrylic acid ethyl ester

2-Cyano-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxa-borolan-2-yl)-phenyl]-acrylic acid ethyl ester

C18H22BNO4 (327.16418020000003)


   

1-benzyl-4,4-diphenylpiperidine

1-benzyl-4,4-diphenylpiperidine

C24H25N (327.198689)


   

N-Tetradecanoyl-4-hydroxy-L-proline

N-Tetradecanoyl-4-hydroxy-L-proline

C18H33NO4 (327.2409458)


   

(2-hydroxyethyl)ammonium decyl sulphate

(2-hydroxyethyl)ammonium decyl sulphate

C14H33NO5S (327.20793280000004)


   

(2E)-2-(HYDROXYIMINO)-N-(2-METHOXY-4-NITROPHENYL)ACETAMIDE

(2E)-2-(HYDROXYIMINO)-N-(2-METHOXY-4-NITROPHENYL)ACETAMIDE

C23H21NO (327.1623056)


   
   

Dimenoxadol

2-(dimethylamino)ethyl 2-ethoxy-2,2-diphenylacetate

C20H25NO3 (327.18343400000003)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent

   

(2R,3S)-1-CARBOXY-4-TRIFLUOROMETHYL-2,3-DIHYDROXYCYCLOHEXA-4,6-DIENE

(2R,3S)-1-CARBOXY-4-TRIFLUOROMETHYL-2,3-DIHYDROXYCYCLOHEXA-4,6-DIENE

C21H29NO2 (327.2198174)


   

CP-101,606

CP-101,606

C20H25NO3 (327.18343400000003)


Traxoprodil (CP101,606) is a potent and selective NMDA antagonist and protect hippocampal neurons with an IC50 of 10 nM.

   

Cyclopentolate Hydrochloride

Cyclopentolate Hydrochloride

C17H26ClNO3 (327.16011160000005)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D009184 - Mydriatics C78283 - Agent Affecting Organs of Special Senses > C29706 - Mydriatic Agent Cyclopentolate (DL-Cyclopentolate) hydrochloride is an Atropine-like muscarinic receptors antagonist with a pKB value of 7.8 (on the circular ciliary muscle). Cyclopentolate hydrochloride is an anti-muscarinic agent commonly used in the ophthalmologic practice[1][2].

   

2-(TERT-BUTYL)-7-PIPERAZINO-5-(TRIFLUOROMETHYL)PYRAZOLO[1,5-A]PYRIMIDINE

2-(TERT-BUTYL)-7-PIPERAZINO-5-(TRIFLUOROMETHYL)PYRAZOLO[1,5-A]PYRIMIDINE

C15H20F3N5 (327.16707160000004)


   

tert-butyl 3-(4-phenyl-1H-imidazol-2-yl)piperidine-1-carboxylate

tert-butyl 3-(4-phenyl-1H-imidazol-2-yl)piperidine-1-carboxylate

C19H25N3O2 (327.194667)


   

9-Ethyl-3-(N-methyl-N-phenylhydrazonomethyl)carbazole

9-Ethyl-3-(N-methyl-N-phenylhydrazonomethyl)carbazole

C22H21N3 (327.17353860000003)


   
   
   

1,3,3-trimethylspiro[benzo[f]chromene-3,2-indole]

1,3,3-trimethylspiro[benzo[f]chromene-3,2-indole]

C23H21NO (327.1623056)


   

3-(Furfurylaminocarbonyl)benzeneboronic acid pinacol ester

3-(Furfurylaminocarbonyl)benzeneboronic acid pinacol ester

C18H22BNO4 (327.16418020000003)


   

10-Nitrooleic acid

10-Nitrooleic acid

C18H33NO4 (327.2409458)


D000893 - Anti-Inflammatory Agents

   

2,6-Dimethyl-1-(3-[3-methyl-5-isoxazolyl]-propanyl)-4-[4-methyl-2H-tetrazol-2-YL]-phenol

2,6-Dimethyl-1-(3-[3-methyl-5-isoxazolyl]-propanyl)-4-[4-methyl-2H-tetrazol-2-YL]-phenol

C17H21N5O2 (327.1695166)


   

Ortho Evra

Deacetylnorgestimate

C21H29NO2 (327.2198174)


D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents

   

Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-((4-methoxyphenyl)methyl)-2-methyl-

Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-((4-methoxyphenyl)methyl)-2-methyl-

C20H25NO3 (327.18343400000003)


   

Thiphenamil

Thiphenamil

C20H25NOS (327.165676)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent

   
   

3,5-diethyl-2-(2-hydroxyethylamino)-5-methyl-6H-benzo[h]quinazolin-4-one

3,5-diethyl-2-(2-hydroxyethylamino)-5-methyl-6H-benzo[h]quinazolin-4-one

C19H25N3O2 (327.194667)


   

3-Methyl-7-(2-phenylethyl)-8-(propylamino)purine-2,6-dione

3-Methyl-7-(2-phenylethyl)-8-(propylamino)purine-2,6-dione

C17H21N5O2 (327.1695166)


   

beta-Aminoarteether

beta-Aminoarteether

C17H29NO5 (327.2045624)


   

17-Methyl-androsta-2,4-dieno(2,3-d)isoxazol-17-ol, (17beta)-

17-Methyl-androsta-2,4-dieno(2,3-d)isoxazol-17-ol, (17beta)-

C21H29NO2 (327.2198174)


   

UR-144 N-(2-hydroxypentyl) metabolite

UR-144 N-(2-hydroxypentyl) metabolite

C21H29NO2 (327.2198174)


   

2-(beta-Diethylaminopropionyl)-5,7-dimethyl-1,2,3,4-tetrahydropyrimido(3,4-a)indole

2-(beta-Diethylaminopropionyl)-5,7-dimethyl-1,2,3,4-tetrahydropyrimido(3,4-a)indole

C20H29N3O (327.2310504)


   

Norelgestromin

Deacetylnorgestimate

C21H29NO2 (327.2198174)


C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents

   

2,6-Dimethyl-1-(3-[3-methyl-5-isoxazolyl]-propanyl)-4-[2n-methyl-2h-tetrazol-5-yl]-phenol

2,6-Dimethyl-1-(3-[3-methyl-5-isoxazolyl]-propanyl)-4-[2n-methyl-2h-tetrazol-5-yl]-phenol

C17H21N5O2 (327.1695166)


   

N-(Trans-4-{(1s,2s)-2-Amino-3-[(3s)-3-Fluoropyrrolidin-1-Yl]-1-Methyl-3-Oxopropyl}cyclohexyl)-N-Methylacetamide

N-(Trans-4-{(1s,2s)-2-Amino-3-[(3s)-3-Fluoropyrrolidin-1-Yl]-1-Methyl-3-Oxopropyl}cyclohexyl)-N-Methylacetamide

C17H30FN3O2 (327.2321932)


   

terbinafine hydrochloride

terbinafine hydrochloride

C21H26ClN (327.1753666000001)


D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent D004791 - Enzyme Inhibitors Terbinafine hydrochloride (TDT 067 hydrochloride) is an orally active and potent antifungal agent. Terbinafine hydrochloride is a potent non-competitive inhibitor of squalene epoxidase from Candida, with a Ki of 30 nM. Terbinafine hydrochloride also shows antibacterial activity against certain Gram-positive and Gram-negative bacteria[1][2][3]. Terbinafine hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

   
   

(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoate

(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoate

C22H31O2- (327.23239259999997)


A polyunsaturated fatty acid anion that is the conjugate base of (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

Nbeta-methylnorajmaline

Nbeta-methylnorajmaline

C20H27N2O2+ (327.2072422)


   

N-propanoyl-gamma-L-glutamyl-L-orornithine-delta-lactam ethyl ester

N-propanoyl-gamma-L-glutamyl-L-orornithine-delta-lactam ethyl ester

C15H25N3O5 (327.179412)


   

(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[(E,4R,5S)-5-hydroxy-4-methylhex-2-enyl]oxan-2-yl]-3-methylbut-2-enoate

(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[(E,4R,5S)-5-hydroxy-4-methylhex-2-enyl]oxan-2-yl]-3-methylbut-2-enoate

C17H27O6- (327.1807542)


   

(E)-2-nitrooctadec-9-enoic acid

(E)-2-nitrooctadec-9-enoic acid

C18H33NO4 (327.2409458)


D000893 - Anti-Inflammatory Agents

   

3,4-dimethylideneheptanedioylcarnitine

3,4-dimethylideneheptanedioylcarnitine

C16H25NO6 (327.168179)


   

13-Ethyl-17-ethynyl-3-nitroso-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol (non-preferred name)

13-Ethyl-17-ethynyl-3-nitroso-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol (non-preferred name)

C21H29NO2 (327.2198174)


   

Undec-3-enoylcarnitine

Undec-3-enoylcarnitine

C18H33NO4 (327.2409458)


   

Undec-9-enoylcarnitine

Undec-9-enoylcarnitine

C18H33NO4 (327.2409458)


   

Undec-8-enoylcarnitine

Undec-8-enoylcarnitine

C18H33NO4 (327.2409458)


   

Nona-4,7-dienedioylcarnitine

Nona-4,7-dienedioylcarnitine

C16H25NO6 (327.168179)


   

Nona-3,7-dienedioylcarnitine

Nona-3,7-dienedioylcarnitine

C16H25NO6 (327.168179)


   

Nona-4,6-dienedioylcarnitine

Nona-4,6-dienedioylcarnitine

C16H25NO6 (327.168179)


   

Nona-3,6-dienedioylcarnitine

Nona-3,6-dienedioylcarnitine

C16H25NO6 (327.168179)


   

Nona-5,7-dienedioylcarnitine

Nona-5,7-dienedioylcarnitine

C16H25NO6 (327.168179)


   

(6E)-Undec-6-enoylcarnitine

(6E)-Undec-6-enoylcarnitine

C18H33NO4 (327.2409458)


   

(2E)-Undec-2-enoylcarnitine

(2E)-Undec-2-enoylcarnitine

C18H33NO4 (327.2409458)


   

(5E)-Undec-5-enoylcarnitine

(5E)-Undec-5-enoylcarnitine

C18H33NO4 (327.2409458)


   

(4E)-Undec-4-enoylcarnitine

(4E)-Undec-4-enoylcarnitine

C18H33NO4 (327.2409458)


   

(7E)-Undec-7-enoylcarnitine

(7E)-Undec-7-enoylcarnitine

C18H33NO4 (327.2409458)


   

18-Nitrooctadec-9-enoic acid

18-Nitrooctadec-9-enoic acid

C18H33NO4 (327.2409458)


   

(2E,7E)-Nona-2,7-dienedioylcarnitine

(2E,7E)-Nona-2,7-dienedioylcarnitine

C16H25NO6 (327.168179)


   

(4E,6Z)-3-Hydroxydeca-4,6-dienoylcarnitine

(4E,6Z)-3-Hydroxydeca-4,6-dienoylcarnitine

C17H29NO5 (327.2045624)


   

(6Z,8E)-3-Hydroxydeca-6,8-dienoylcarnitine

(6Z,8E)-3-Hydroxydeca-6,8-dienoylcarnitine

C17H29NO5 (327.2045624)


   

(4E,7E)-3-Hydroxydeca-4,7-dienoylcarnitine

(4E,7E)-3-Hydroxydeca-4,7-dienoylcarnitine

C17H29NO5 (327.2045624)


   

(5Z,7E)-3-Hydroxydeca-5,7-dienoylcarnitine

(5Z,7E)-3-Hydroxydeca-5,7-dienoylcarnitine

C17H29NO5 (327.2045624)


   

(E)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]tetradec-5-enoate

(E)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]tetradec-5-enoate

C18H33NO4 (327.2409458)


   

Ajmalinium

Ajmalinium

C20H27N2O2+ (327.2072422)


Conjugate acid of ajmaline.

   

1,1-Diethyl-2,2-cyanine

1,1-Diethyl-2,2-cyanine

C23H23N2+ (327.1861138)


   

3-[(4-ethoxyphenoxy)methyl]-N,N-diethylbenzamide

3-[(4-ethoxyphenoxy)methyl]-N,N-diethylbenzamide

C20H25NO3 (327.18343400000003)


   
   

Glyoxal-lysine dimer

Glyoxal-lysine dimer

C15H27N4O4+ (327.20322020000003)


An imidazolium ion formed via cyclo-dimerisation of L-lysine and glyoxal.

   

N-[4-(4-propanoylpiperazin-1-yl)phenyl]furan-2-carboxamide

N-[4-(4-propanoylpiperazin-1-yl)phenyl]furan-2-carboxamide

C18H21N3O3 (327.1582836)


   

5-(Azepan-1-yl)-2-(3,4-dimethoxyphenyl)-1,3-oxazole-4-carbonitrile

5-(Azepan-1-yl)-2-(3,4-dimethoxyphenyl)-1,3-oxazole-4-carbonitrile

C18H21N3O3 (327.1582836)


   

3-[[5,5-dimethyl-3-(4-morpholinyl)-1-cyclohex-2-enylidene]amino]-N,N-dimethylaniline

3-[[5,5-dimethyl-3-(4-morpholinyl)-1-cyclohex-2-enylidene]amino]-N,N-dimethylaniline

C20H29N3O (327.2310504)


   

[4-(2-Ethoxyphenyl)-1-piperazinyl]-(1-oxido-4-pyridin-1-iumyl)methanone

[4-(2-Ethoxyphenyl)-1-piperazinyl]-(1-oxido-4-pyridin-1-iumyl)methanone

C18H21N3O3 (327.1582836)


   

1-(3,5-Dimethylphenyl)-3-(9-prop-2-enyl-9-azabicyclo[3.3.1]nonan-3-yl)urea

1-(3,5-Dimethylphenyl)-3-(9-prop-2-enyl-9-azabicyclo[3.3.1]nonan-3-yl)urea

C20H29N3O (327.2310504)


   

7-methyl-3-(3-methylbutylamino)-1-(1-pyrrolidinyl)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile

7-methyl-3-(3-methylbutylamino)-1-(1-pyrrolidinyl)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile

C19H29N5 (327.2422834)


   

1-[(2,4-Dimethoxy-3-methylphenyl)methyl]-4-(2-pyridinyl)piperazine

1-[(2,4-Dimethoxy-3-methylphenyl)methyl]-4-(2-pyridinyl)piperazine

C19H25N3O2 (327.194667)


   

1-[(1-Tert-butyl-5-tetrazolyl)-(4-methylphenyl)methyl]-4-methylpiperidine

1-[(1-Tert-butyl-5-tetrazolyl)-(4-methylphenyl)methyl]-4-methylpiperidine

C19H29N5 (327.2422834)


   

N-[2-(3,4-diethoxyphenyl)ethyl]-2-phenylacetamide

N-[2-(3,4-diethoxyphenyl)ethyl]-2-phenylacetamide

C20H25NO3 (327.18343400000003)


   

Thr-Ala-His

Thr-Ala-His

C13H21N5O5 (327.15426160000004)


A tripeptide composed of L-threonine, L-alanine, and L-histidine joined by peptide linkages.

   
   

N-(2,4-dimethylphenyl)-4-{2-[(5-methyl-2-furyl)methylene]hydrazino}-4-oxobutanamide

N-(2,4-dimethylphenyl)-4-{2-[(5-methyl-2-furyl)methylene]hydrazino}-4-oxobutanamide

C18H21N3O3 (327.1582836)


   

[1-(Dimethylamino)-2-methylpropan-2-yl] 2-hydroxy-2,2-diphenylacetate

[1-(Dimethylamino)-2-methylpropan-2-yl] 2-hydroxy-2,2-diphenylacetate

C20H25NO3 (327.18343400000003)


   

(2R,3R,4R)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile

(2R,3R,4R)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile

C19H25N3O2 (327.194667)


   

N-cyclobutyl-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2R,5R,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2R,5R,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2S,5S,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2S,5S,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2S,5R,6R)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2S,5R,6R)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

(2R,3S,4R)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile

(2R,3S,4R)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile

C19H25N3O2 (327.194667)


   

N-cyclobutyl-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

N-cyclobutyl-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

N-cyclobutyl-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[oxo(propylamino)methyl]amino]-2-oxanyl]acetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2R,5S,6R)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2R,5S,6R)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2S,5R,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2S,5R,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2S,5S,6R)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2S,5S,6R)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

2-[(2R,5S,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

2-[(2R,5S,6S)-5-[[(cyclopentylamino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N,N-dimethylacetamide

C16H29N3O4 (327.21579540000005)


   

(2S,3S,4R)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile

(2S,3S,4R)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile

C19H25N3O2 (327.194667)


   

(2S,3S,4S)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile

(2S,3S,4S)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile

C19H25N3O2 (327.194667)


   
   
   
   

(12R,13S)-epoxy-(10R)-hydroperoxy-(8E)-octadecenoate

(12R,13S)-epoxy-(10R)-hydroperoxy-(8E)-octadecenoate

C18H31O5- (327.2171376)


   

(11Z)-10,11-Dihydro-8-(1-methylethyl)-11-(2-methylpropylidene)-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione

(11Z)-10,11-Dihydro-8-(1-methylethyl)-11-(2-methylpropylidene)-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione

C18H21N3O3 (327.1582836)


   

2-Aminoethyl (2-hydroxy-3-octoxypropyl) hydrogen phosphate

2-Aminoethyl (2-hydroxy-3-octoxypropyl) hydrogen phosphate

C13H30NO6P (327.18106500000005)


   

(2-Hydroxy-3-pentoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

(2-Hydroxy-3-pentoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C13H30NO6P (327.18106500000005)


   

butorphanol

butorphanol

C21H29NO2 (327.2198174)


Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AF - Morphinan derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists D019141 - Respiratory System Agents > D000996 - Antitussive Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics

   

(9E)-10-nitrooctadecenoic Acid

(9E)-10-nitrooctadecenoic Acid

C18H33NO4 (327.2409458)


A nitro fatty acid that is (9E)-octadec-9-enoic (elaidic) acid substituted by a nitro group at position 10.

   

1-[(2E,8E)-9-(3,4-methylenedioxyphenyl)-2,8-nonadienoyl]pyrrolidine

1-[(2E,8E)-9-(3,4-methylenedioxyphenyl)-2,8-nonadienoyl]pyrrolidine

C20H25NO3 (327.18343400000003)


A natural product found in Piper boehmeriaefolium.

   
   

3-hydroxy-N-(2-oxooxolan-3-yl)tetradecanamide

3-hydroxy-N-(2-oxooxolan-3-yl)tetradecanamide

C18H33NO4 (327.2409458)


   

1-pentyl-sn-glycero-3-phosphocholine

1-pentyl-sn-glycero-3-phosphocholine

C13H30NO6P (327.18106500000005)


   

17-Methylandrosta-2,4-dieno[2,3-d]isoxazol-17beta-ol

17-Methylandrosta-2,4-dieno[2,3-d]isoxazol-17beta-ol

C21H29NO2 (327.2198174)


   

Docosahexaenoate

Docosahexaenoate

C22H31O2 (327.23239259999997)


A polyunsaturated fatty acid anion that is the conjugate base of docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

O-undecenoylcarnitine

O-undecenoylcarnitine

C18H33NO4 (327.2409458)


An O-acylcarnitine in which the acyl group is specified as undecenoyl (position of double bond not specified).

   

O-(dimethylnonenoyl)carnitine

O-(dimethylnonenoyl)carnitine

C18H33NO4 (327.2409458)


An O-acylcarnitine in which the acyl group is specified as dimethylnonenoyl (positions of double bond and methyl groups not specified).

   

(9E)-9-nitrooctadecenoic Acid

(9E)-9-nitrooctadecenoic Acid

C18H33NO4 (327.2409458)


A nitro fatty acid that is (9E)-octadec-9-enoic (elaidic) acid substituted by a nitro group at position 9.

   

AcCa(11:1)

Acetyl-CoA carboxylase-alpha(11:1)

C18H33NO4 (327.2409458)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   
   

Zelquistinel

Zelquistinel

C15H25N3O5 (327.179412)


Zelquistinel (AGN-241751) is a N-methyl-D-aspartate (NMDA) receptor partial agonist used for the research of depression, anxiety and other related psychiatric disorders[1].

   

undecenoylcarnitine

3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]tetradec-5-enoate

C18H33NO4 (327.2409458)


new metabolite created

   

(1r,4s,5r,6s,10r,16r)-5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadecane-3,7-dione

(1r,4s,5r,6s,10r,16r)-5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadecane-3,7-dione

C16H25NO6 (327.168179)


   

9-methoxy-4-(2-methylprop-2-en-1-yl)-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol

9-methoxy-4-(2-methylprop-2-en-1-yl)-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol

C20H25NO3 (327.18343400000003)


   

4-(5-ethyl-3-methyloxolan-2-yl)-4-hydroxy-n-(1-hydroxy-3-methylpentan-2-yl)pent-2-enimidic acid

4-(5-ethyl-3-methyloxolan-2-yl)-4-hydroxy-n-(1-hydroxy-3-methylpentan-2-yl)pent-2-enimidic acid

C18H33NO4 (327.2409458)


   

(1r)-7-methoxy-1-[(4-methoxyphenyl)methyl]-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium-8-olate

(1r)-7-methoxy-1-[(4-methoxyphenyl)methyl]-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium-8-olate

C20H25NO3 (327.18343400000003)


   

(1s,5s,8r,9s,10s,11r,14r,16s,17r,18r,19r)-10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

(1s,5s,8r,9s,10s,11r,14r,16s,17r,18r,19r)-10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

C20H25NO3 (327.18343400000003)


   

n-(1-hydroxy-3-methylpentan-2-yl)-3-[3-(4-hydroxyhexan-2-yl)-2-methyloxiran-2-yl]prop-2-enimidic acid

n-(1-hydroxy-3-methylpentan-2-yl)-3-[3-(4-hydroxyhexan-2-yl)-2-methyloxiran-2-yl]prop-2-enimidic acid

C18H33NO4 (327.2409458)


   

(2s)-2-({[(2s)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-4-methylpentanoic acid

(2s)-2-({[(2s)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-4-methylpentanoic acid

C16H29N3O4 (327.21579540000005)


   

3-epifortuneine

NA

C20H25NO3 (327.18343400000003)


{"Ingredient_id": "HBIN008478","Ingredient_name": "3-epifortuneine","Alias": "NA","Ingredient_formula": "C20H25NO3","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6915","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1r,7s)-7-{[(2,3-dihydroxypropanoyl)oxy]methyl}-hexahydro-1h-pyrrolizin-1-yl (2e)-2-methylbut-2-enoate

(1r,7s)-7-{[(2,3-dihydroxypropanoyl)oxy]methyl}-hexahydro-1h-pyrrolizin-1-yl (2e)-2-methylbut-2-enoate

C16H25NO6 (327.168179)


   

9-(2h-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)nona-2,8-dien-1-one

9-(2h-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)nona-2,8-dien-1-one

C20H25NO3 (327.18343400000003)


   

6,11-dihydroxy-13-methyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-6,14,17-trien-16-one

6,11-dihydroxy-13-methyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-6,14,17-trien-16-one

C20H25NO3 (327.18343400000003)


   

3,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-one

3,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-one

C20H25NO3 (327.18343400000003)


   

(1r,2r,4s,7s,8e,13s,14z,16e,18r,19s,20s)-13-methyl-21-oxa-11-azatetracyclo[16.2.1.0⁴,²⁰.0⁷,¹⁹]henicosa-5,8,10,14,16-pentaene-2,10-diol

(1r,2r,4s,7s,8e,13s,14z,16e,18r,19s,20s)-13-methyl-21-oxa-11-azatetracyclo[16.2.1.0⁴,²⁰.0⁷,¹⁹]henicosa-5,8,10,14,16-pentaene-2,10-diol

C20H25NO3 (327.18343400000003)


   

(1s,5r,8r,9s,10r,11r,14r,16s,17r,18r,19s)-10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

(1s,5r,8r,9s,10r,11r,14r,16s,17r,18r,19s)-10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

C20H25NO3 (327.18343400000003)


   

4-(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl 1-methyl (2r)-2-hydroxy-2-(2-methylpropyl)butanedioate

4-(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl 1-methyl (2r)-2-hydroxy-2-(2-methylpropyl)butanedioate

C17H29NO5 (327.2045624)


   

(1s,2r,4r,7r,8e,13s,14z,16e,18s,19r,20r)-13-methyl-21-oxa-11-azatetracyclo[16.2.1.0⁴,²⁰.0⁷,¹⁹]henicosa-5,8,10,14,16-pentaene-2,10-diol

(1s,2r,4r,7r,8e,13s,14z,16e,18s,19r,20r)-13-methyl-21-oxa-11-azatetracyclo[16.2.1.0⁴,²⁰.0⁷,¹⁹]henicosa-5,8,10,14,16-pentaene-2,10-diol

C20H25NO3 (327.18343400000003)


   

(1r,5s,8r,9s,11s,13r,14s,16s,17r,18s)-10,13-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

(1r,5s,8r,9s,11s,13r,14s,16s,17r,18s)-10,13-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

C20H25NO3 (327.18343400000003)


   

(2r)-2-[(3r)-3-hydroxy-4-methylpentyl]-2,6-dimethylpyrano[3,2-c]quinolin-5-one

(2r)-2-[(3r)-3-hydroxy-4-methylpentyl]-2,6-dimethylpyrano[3,2-c]quinolin-5-one

C20H25NO3 (327.18343400000003)


   

(1s,5s,8r,9s,11r,14r,16s,17r,18r,19s)-10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

(1s,5s,8r,9s,11r,14r,16s,17r,18r,19s)-10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

C20H25NO3 (327.18343400000003)


   

4-(pent-4-enoyl)-4,7,15-triazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadeca-10,12-dien-14-one

4-(pent-4-enoyl)-4,7,15-triazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadeca-10,12-dien-14-one

C19H25N3O2 (327.194667)


   

4-hexahydro-1h-pyrrolizin-1-ylmethyl 1-methyl 2-hydroxy-2-(2-methylpropyl)butanedioate

4-hexahydro-1h-pyrrolizin-1-ylmethyl 1-methyl 2-hydroxy-2-(2-methylpropyl)butanedioate

C17H29NO5 (327.2045624)


   

(1r,3s,5s,8r,9s,11s,14r,16r,17r,18r)-3,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-one

(1r,3s,5s,8r,9s,11s,14r,16r,17r,18r)-3,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-one

C20H25NO3 (327.18343400000003)


   

(1r,5s,8r,9s,10s,11s,14r,16r,17r,18r)-10,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

(1r,5s,8r,9s,10s,11s,14r,16r,17r,18r)-10,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

C20H25NO3 (327.18343400000003)


   

(2e)-n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]-3-[(2r)-3-[(2s,4r)-4-hydroxyhexan-2-yl]-2-methyloxiran-2-yl]prop-2-enimidic acid

(2e)-n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]-3-[(2r)-3-[(2s,4r)-4-hydroxyhexan-2-yl]-2-methyloxiran-2-yl]prop-2-enimidic acid

C18H33NO4 (327.2409458)


   

(2e)-4-[(2r,3s,5r)-5-ethyl-3-methyloxolan-2-yl]-4-hydroxy-n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]pent-2-enimidic acid

(2e)-4-[(2r,3s,5r)-5-ethyl-3-methyloxolan-2-yl]-4-hydroxy-n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]pent-2-enimidic acid

C18H33NO4 (327.2409458)


   

(4s)-4-[(2r,3s,5r)-5-ethyl-3-methyloxolan-2-yl]-4-hydroxy-n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]pent-2-enimidic acid

(4s)-4-[(2r,3s,5r)-5-ethyl-3-methyloxolan-2-yl]-4-hydroxy-n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]pent-2-enimidic acid

C18H33NO4 (327.2409458)


   

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s)-2-[(1r)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s)-2-[(1r)-1-(acetyloxy)ethyl]-2-hydroxy-3-methylbutanoate

C17H29NO5 (327.2045624)


   

7-chloro-3-(4-cyclopropyl-2-methylbuta-1,3-dien-1-yl)-1-methyl-hexahydro-2h-indolizine-1,2,8-triol

7-chloro-3-(4-cyclopropyl-2-methylbuta-1,3-dien-1-yl)-1-methyl-hexahydro-2h-indolizine-1,2,8-triol

C17H26ClNO3 (327.16011160000005)


   

4,14-dihydroxy-5-isopropyl-6,9-dimethyl-15-azatetracyclo[7.6.1.0²,⁶.0¹³,¹⁶]hexadeca-1,4,12,14-tetraen-3-one

4,14-dihydroxy-5-isopropyl-6,9-dimethyl-15-azatetracyclo[7.6.1.0²,⁶.0¹³,¹⁶]hexadeca-1,4,12,14-tetraen-3-one

C20H25NO3 (327.18343400000003)


   

3-hydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

3-hydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

C21H29NO2 (327.2198174)


   

4,5,16-trimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2,4,6,13,15-hexaene

4,5,16-trimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2,4,6,13,15-hexaene

C20H25NO3 (327.18343400000003)


   

(1s,2r,9s)-4-(pent-4-enoyl)-4,7,15-triazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadeca-10,12-dien-14-one

(1s,2r,9s)-4-(pent-4-enoyl)-4,7,15-triazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadeca-10,12-dien-14-one

C19H25N3O2 (327.194667)


   

(1r,3s,5r,8r,9s,11s,14r,16r,17r,18r)-3,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-one

(1r,3s,5r,8r,9s,11s,14r,16r,17r,18r)-3,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-10-one

C20H25NO3 (327.18343400000003)


   

(4e)-6-hydroxy-7-isopropyl-4-(2-methylpropylidene)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one

(4e)-6-hydroxy-7-isopropyl-4-(2-methylpropylidene)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one

C18H21N3O3 (327.1582836)


   

(1s)-7-methoxy-1-[2-(4-methoxyphenyl)ethyl]-2-methyl-3,4-dihydro-1h-isoquinolin-6-ol

(1s)-7-methoxy-1-[2-(4-methoxyphenyl)ethyl]-2-methyl-3,4-dihydro-1h-isoquinolin-6-ol

C20H25NO3 (327.18343400000003)


   

11-hydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

11-hydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

C21H29NO2 (327.2198174)


   

(1s,12s,14r)-9-methoxy-4-(2-methylprop-2-en-1-yl)-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol

(1s,12s,14r)-9-methoxy-4-(2-methylprop-2-en-1-yl)-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol

C20H25NO3 (327.18343400000003)


   

5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadecane-3,7-dione

5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadecane-3,7-dione

C16H25NO6 (327.168179)


   

(1s,2s,5s,9r,11r,12s,13r)-6,11-dihydroxy-13-methyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-6,14,17-trien-16-one

(1s,2s,5s,9r,11r,12s,13r)-6,11-dihydroxy-13-methyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-6,14,17-trien-16-one

C20H25NO3 (327.18343400000003)


   

(2e,4s)-4-[(2r,3s,5r)-5-ethyl-3-methyloxolan-2-yl]-4-hydroxy-n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]pent-2-enimidic acid

(2e,4s)-4-[(2r,3s,5r)-5-ethyl-3-methyloxolan-2-yl]-4-hydroxy-n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]pent-2-enimidic acid

C18H33NO4 (327.2409458)


   

(1s,2s,5s,6s,9r,11r,12s,13r)-11-hydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

(1s,2s,5s,6s,9r,11r,12s,13r)-11-hydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

C21H29NO2 (327.2198174)


   

(1r,5r,8r,9s,10r,11s,13r,14s,16s,17r,18s)-10,13-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

(1r,5r,8r,9s,10r,11s,13r,14s,16s,17r,18s)-10,13-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

C20H25NO3 (327.18343400000003)


   

10,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

10,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

C20H25NO3 (327.18343400000003)


   

(5r,9s,11s,16s,17r,18r)-10,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one

(5r,9s,11s,16s,17r,18r)-10,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one

C20H25NO3 (327.18343400000003)


   

9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)nona-2,4,8-trienimidic acid

9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)nona-2,4,8-trienimidic acid

C20H25NO3 (327.18343400000003)


   

19-hydroxy-5-methyl-18-methylidene-9-oxa-11-azaheptacyclo[15.2.1.0¹,¹⁴.0²,¹².0⁴,¹³.0⁵,¹⁰.0⁸,¹³]icosan-16-one

19-hydroxy-5-methyl-18-methylidene-9-oxa-11-azaheptacyclo[15.2.1.0¹,¹⁴.0²,¹².0⁴,¹³.0⁵,¹⁰.0⁸,¹³]icosan-16-one

C20H25NO3 (327.18343400000003)


   

(1r)-7,8-dimethoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinoline

(1r)-7,8-dimethoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinoline

C20H25NO3 (327.18343400000003)


   

8-methyl-16-methylidene-6-oxa-11-azaoctacyclo[8.7.1.1²,¹⁵.1⁵,⁸.0¹,¹³.0³,⁹.0³,¹².0⁷,¹¹]icosane-14,19-diol

8-methyl-16-methylidene-6-oxa-11-azaoctacyclo[8.7.1.1²,¹⁵.1⁵,⁸.0¹,¹³.0³,⁹.0³,¹².0⁷,¹¹]icosane-14,19-diol

C20H25NO3 (327.18343400000003)


   

3-[2-(dimethylamino)ethyl]-6-methoxy-2-[(1e)-2-(4-methoxyphenyl)ethenyl]phenol

3-[2-(dimethylamino)ethyl]-6-methoxy-2-[(1e)-2-(4-methoxyphenyl)ethenyl]phenol

C20H25NO3 (327.18343400000003)


   

(1s)-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinoline

(1s)-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinoline

C20H25NO3 (327.18343400000003)


   

(2s,3r,4s,5s,6r)-2-{4-[2-(dimethylamino)ethyl]phenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3r,4s,5s,6r)-2-{4-[2-(dimethylamino)ethyl]phenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C16H25NO6 (327.168179)


   

(1r,2s,3s,5s,6s,9s,12s,13r)-3-hydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

(1r,2s,3s,5s,6s,9s,12s,13r)-3-hydroxy-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

C21H29NO2 (327.2198174)


   

(1r,2r,3s,5r,7r,8r,9s,10s,12r,13s,14r,15r,19s)-8-methyl-16-methylidene-6-oxa-11-azaoctacyclo[8.7.1.1²,¹⁵.1⁵,⁸.0¹,¹³.0³,⁹.0³,¹².0⁷,¹¹]icosane-14,19-diol

(1r,2r,3s,5r,7r,8r,9s,10s,12r,13s,14r,15r,19s)-8-methyl-16-methylidene-6-oxa-11-azaoctacyclo[8.7.1.1²,¹⁵.1⁵,⁸.0¹,¹³.0³,⁹.0³,¹².0⁷,¹¹]icosane-14,19-diol

C20H25NO3 (327.18343400000003)


   

(2e)-n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]-3-[(2r,3s)-3-[(2s,4r)-4-hydroxyhexan-2-yl]-2-methyloxiran-2-yl]prop-2-enimidic acid

(2e)-n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]-3-[(2r,3s)-3-[(2s,4r)-4-hydroxyhexan-2-yl]-2-methyloxiran-2-yl]prop-2-enimidic acid

C18H33NO4 (327.2409458)


   

(1r)-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinoline

(1r)-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinoline

C20H25NO3 (327.18343400000003)


   

(1r,7s)-7-{[(2,3-dihydroxypropanoyl)oxy]methyl}-hexahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate

(1r,7s)-7-{[(2,3-dihydroxypropanoyl)oxy]methyl}-hexahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate

C16H25NO6 (327.168179)


   

n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]-3-[(2r,3s)-3-[(2s,4r)-4-hydroxyhexan-2-yl]-2-methyloxiran-2-yl]prop-2-enimidic acid

n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]-3-[(2r,3s)-3-[(2s,4r)-4-hydroxyhexan-2-yl]-2-methyloxiran-2-yl]prop-2-enimidic acid

C18H33NO4 (327.2409458)


   

hexahydro-1h-pyrrolizin-1-ylmethyl 3-(acetyloxy)-2-hydroxy-2-isopropylbutanoate

hexahydro-1h-pyrrolizin-1-ylmethyl 3-(acetyloxy)-2-hydroxy-2-isopropylbutanoate

C17H29NO5 (327.2045624)


   

(1r,5r,8r,9s,10s,11s,14r,16r,17r,18r)-10,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

(1r,5r,8r,9s,10s,11s,14r,16r,17r,18r)-10,16-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

C20H25NO3 (327.18343400000003)


   

(6r,9s,16s)-4,14-dihydroxy-5-isopropyl-6,9-dimethyl-15-azatetracyclo[7.6.1.0²,⁶.0¹³,¹⁶]hexadeca-1,4,12,14-tetraen-3-one

(6r,9s,16s)-4,14-dihydroxy-5-isopropyl-6,9-dimethyl-15-azatetracyclo[7.6.1.0²,⁶.0¹³,¹⁶]hexadeca-1,4,12,14-tetraen-3-one

C20H25NO3 (327.18343400000003)


   

[(2-amino-5-carbamimidamido-1-hydroxypentylidene)amino](1-hydroxy-2-oxocyclopent-3-en-1-yl)acetic acid

[(2-amino-5-carbamimidamido-1-hydroxypentylidene)amino](1-hydroxy-2-oxocyclopent-3-en-1-yl)acetic acid

C13H21N5O5 (327.15426160000004)


   

(2e,4e,8e)-9-(2h-1,3-benzodioxol-5-yl)-n-[(2r)-butan-2-yl]nona-2,4,8-trienimidic acid

(2e,4e,8e)-9-(2h-1,3-benzodioxol-5-yl)-n-[(2r)-butan-2-yl]nona-2,4,8-trienimidic acid

C20H25NO3 (327.18343400000003)


   

(1s,2s,3s,7s,8s,8ar)-7-chloro-3-[(1e,3e)-4-cyclopropyl-2-methylbuta-1,3-dien-1-yl]-1-methyl-hexahydro-2h-indolizine-1,2,8-triol

(1s,2s,3s,7s,8s,8ar)-7-chloro-3-[(1e,3e)-4-cyclopropyl-2-methylbuta-1,3-dien-1-yl]-1-methyl-hexahydro-2h-indolizine-1,2,8-triol

C17H26ClNO3 (327.16011160000005)


   

2-{4-[2-(dimethylamino)ethyl]phenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

2-{4-[2-(dimethylamino)ethyl]phenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C16H25NO6 (327.168179)


   

(5r,10r,19s)-10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

(5r,10r,19s)-10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

C20H25NO3 (327.18343400000003)


   

10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-one

C20H25NO3 (327.18343400000003)


   

(2e,4e,8e)-9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)nona-2,4,8-trienimidic acid

(2e,4e,8e)-9-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)nona-2,4,8-trienimidic acid

C20H25NO3 (327.18343400000003)